and bispecific antibodies for cancer. Boshoff will retain overall responsibility for Pfizer's dedicated oncology R&D operation, whose structure will remain unchanged from what was announced ...

The drop in Hudson’s pay also coincided with a future-looking adjustment in the payment structure for the CEO post ... $600 million upfront buyout of Dren Bio’s clinical stage bispecific antibody. The ...

Motivity, a leader in clinical SaaS solutions for Applied Behavior Analysis (ABA) providers, today announced the expansion of the Motivity platform to include a complete all-in-one, enterprise-ready ...

Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the United States Food and Drug Administration has granted 510(k) clearance for Backpack® (Porous ...

Over the past two decades, monoclonal antibodies (mAbs) have played a pivotal role in cancer treatment; however, their efficacy as anticancer agents is constrained by tumor heterogeneity and the ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate.

Tharimmune Inc. has announced preclinical data from its expanded pipeline with HS-1940, a dual-target multispecific biologic engineered to bind to both programmed cell death protein 1 (PD-1) and ...

bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...

In a new study, researchers from Huntsman Cancer Institute at the University of Utah (the U) found that 7% of Medicare patients cross state borders for cancer care, and rates were nearly double ...